Exelixis stock price target raised to $41 from $38 at Stifel on NET launch

Published 29/07/2025, 17:54
Exelixis stock price target raised to $41 from $38 at Stifel on NET launch

Investing.com - Stifel raised its price target on Exelixis (NASDAQ:EXEL) to $41.00 from $38.00 on Tuesday, while maintaining a Hold rating on the biopharmaceutical company’s stock. The company, currently valued at $10.15 billion, has demonstrated remarkable financial strength with a perfect Piotroski Score of 9, according to InvestingPro data.

The price target increase primarily reflects upwardly revised probability of success estimates for zanza in NLM mCRC (metastatic colorectal cancer), according to Stifel’s analysis.

Exelixis reported Cabometyx sales that slightly missed Stifel’s and Street expectations, with the company’s second-line neuroendocrine tumor (NET) launch contributing approximately 4% in volume, translating to about $21 million in revenue, which may temper enthusiasm following last quarter’s beat.

Stifel identified the pending disclosure of final median overall survival data from the STELLAR-303 trial (atezo/zanza in third-line metastatic colorectal cancer) in non-liver metastasis patients as the most important near-term catalyst for Exelixis, with complete trial data presentation expected at an upcoming medical conference.

The research firm also noted that Exelixis’s discontinuation of the STELLAR-305 trial (pembro/zanza in first-line SCCHN) appears prudent given competitive positioning and emerging safety and tolerability data for zanza, particularly regarding hypertension.

In other recent news, Exelixis Inc . reported its second-quarter 2025 earnings, revealing an earnings per share (EPS) of $0.75, which exceeded analysts’ expectations of $0.64. The company’s revenue, however, came in at $568 million, slightly below the anticipated $578.46 million. Despite this revenue miss, the positive earnings report reflects strategic advancements within the company. JMP Securities has reiterated its Market Outperform rating for Exelixis, maintaining a price target of $50.00. This decision comes despite a slight miss in net cabozantinib sales, which the firm attributed to new pricing dynamics. JMP Securities noted that the volume growth for cabozantinib remains robust at 18% year-over-year. The firm projects cabozantinib to achieve fiscal year 2025 sales of $2.1 billion, with a long-term sales target of $3 billion. These recent developments highlight the company’s potential for growth despite current challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.